| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3980685 | Cancer Treatment Reviews | 2007 | 7 Pages |
Abstract
SummaryEpstein-Barr virus (EBV) is constantly present in undifferentiated and poorly-differentiated nasopharyngeal cancer. Thus, tumour-associated viral antigens are potential targets for immunotherapy. Recently, both preclinical and early clinical studies have shown that various strategies can enhance EBV-specific immunity. Moreover, significant anti-tumour effect has been observed, and was generally correlated with biological response. The present review discusses the rational for EBV-targeted immunotherapy and summarises the latest developments in this area.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Amine Masmoudi, Nabil Toumi, Afef Khanfir, Lamia Kallel-Slimi, Jamel Daoud, Hela Karray, Mounir Frikha,